Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Drug Delivery and Biomedical Approaches in Inflammatory Diseases
share announcement

Drug Delivery and Biomedical Approaches in Inflammatory Diseases

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 1930

Special Issue Editor

Dr. Gesmi Milcovich

E-Mail Website
Guest Editor
Department of Life Sciences, University of Trieste, Trieste, Italy
Interests: biomaterials; biocompatibility; pharmaceutics; biomolecules; drug delivery; gene delivery; tissue engineering; material sciences; soft matter; self-assembly
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to encompass new challenges in targeted drug delivery due to the spread of inflammatory-based diseased conditions. This Special Issue will publish scientific contributions on (but not limited to) the following topics:

  • Novel drug delivery approaches;
  • Nanotechnology approaches;
  • Targeted biomaterial-based strategies;
  • Targeted drug delivery and comorbidity;
  • Vaccines delivery;
  • Drug delivery challenges (and limitations).

The outbreak of several inflammatory-based diseases has led to millions of deaths and intensive care units collapsing, especially in cases of comorbidity, spread all over the world. An impressive increase in drug delivery options, vaccines, and nanotechnology innovation has been witnessed in recent years, with the challenging need to tailor these for effective biomedical responses.

Novel key mechanisms have been identified; as a consequence, brilliant new strategies are being developed.

Thus, this Special Issue of Biomedicines will include both original research papers and reviews focused on biomaterials, drug delivery strategies, nanotechnology and applied nanosciences-targeted drug delivery in inflammatory diseases. We are positive that the contributions to the present issue will be able to effectively support the research on targeted drug delivery approaches, from the nano- to the macroscale.

Dr. Gesmi Milcovich
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • inflammatory diseases
  • reactive oxygen species
  • responsive biomaterials
  • self-assembly

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 3944 KiB  
Article
Synthesis, Characterization and Biocompatibility Evaluation of Novel Chitosan Lipid Micro-Systems for Modified Release of Diclofenac Sodium
by Ana-Maria Raluca Pauna, Liliana Mititelu Tartau, Maria Bogdan, Andreea-Daniela Meca, Gratiela Eliza Popa, Ana Maria Pelin, Cristian Ilie Drochioi, Daniela Angelica Pricop and Liliana Lacramioara Pavel
Biomedicines 2023, 11(2), 453; https://doi.org/10.3390/biomedicines11020453 - 04 Feb 2023
Cited by 3 | Viewed by 1665
Abstract
The purpose of our study was the obtaining, characterization and biocompatibility estimation of novel carrier systems for diclofenac. Diclofenac is a potent nonsteroidal anti-inflammatory drug with frequent gastrointestinal side effects, impairing the quality of the patient’s life. Original diclofenac-loaded micro-vesicles coated with chitosan [...] Read more.
The purpose of our study was the obtaining, characterization and biocompatibility estimation of novel carrier systems for diclofenac. Diclofenac is a potent nonsteroidal anti-inflammatory drug with frequent gastrointestinal side effects, impairing the quality of the patient’s life. Original diclofenac-loaded micro-vesicles coated with chitosan were prepared and physico-chemical analyzed. We investigated their in vitro hemocompatibility and in vivo biocompatibility in rats. The animals were treated orally as follows: group 1 (Control): distilled water 0.3 mL/100 g body weight; Group 2 (CHIT): 0.3 mL/100 g body weight 0.5% chitosan solution; Group 3 (DCF): 15 mg/kg body weight diclofenac; Group 4 (DCF-ves): lipid vesicles loaded with diclofenac 15 mg/kg body weight. Blood samples were collected for assessing: red blood cells, hemoglobin, hematocrit and leukocyte formula. A series of specific parameters of the liver and kidney function, some markers of immune defense, as well as the activity of some enzymes involved in oxidative processes, were also investigated. At the end of the experiment, the animals were sacrificed and fragments of liver, kidney and stomach were collected for histopathological examination. No blood hemolysis was evidenced by the in vitro test with the administration of diclofenac vesicles. The animals treated with diclofenac lipid vesicles stabilized with chitosan did not display any notable differences in their hematological and biochemical profile compared to control animals. These data correlated with the histological results, which showed the absence of architectural changes in the examined tissues. Biological in vitro and in vivo evaluation revealed that the microvesicles containing diclofenac are biocompatible, with potential to be used as delivery systems to modify the drug release, thus making them an attractive candidate for biomedical applications. Full article
(This article belongs to the Special Issue Drug Delivery and Biomedical Approaches in Inflammatory Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop